Updated Aug 3
Related News
Mar 30, 2026
One Man, His Dog, and ChatGPT: Australia's AI-Powered Vaccine Revolution
Australian tech entrepreneur Paul Cunningham turned to AI, leveraging ChatGPT and AlphaFold, to create a personalized mRNA cancer vaccine for his dog, Rose. Partnering with UNSW, the vaccine was developed in record time, shrinking Rose's tumor significantly. This breakthrough underscores AI's potential in personalized medicine and paves the way for innovations in both veterinary and human healthcare.
AImRNA vaccineChatGPT
Mar 17, 2026
Circadian Rhythms: The New Nightwatch in Heart Attack Defense!
Discover how scientists are exploring the power of circadian rhythms to put immune cells in 'night mode,' significantly reducing heart attack damage. This innovative approach targets the body's biological clock to manage immune responses, curbing inflammation and protecting heart tissue after an infarct. Dive into the latest research breakthroughs that could reshape the future of cardiovascular therapy.
immune cellsheart attackcircadian rhythms
Aug 29, 2025
Exelixis' Strategic Shake-Up: $10 Billion Biotech Giant Lays Off 130 Amidst Market Triumphs
Exelixis, a Bay Area biotech valued at over $10 billion, announces layoffs impacting 130 employees as part of a strategic consolidation. Despite the cuts, the company remains profitable thanks to its flagship drug cabozantinib and is heavily investing in the promising successor zanzalintinib. This move sets Exelixis apart from struggling peers in the regional biotech scene.
Exelixisbiotech layoffscabozantinib